ADMA Biologics Increases FY25 Revenue Exceeds $335M
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics has increased its FY25 revenue forecast to exceed $335 million.
November 08, 2023 | 10:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics has increased its FY25 revenue forecast, which could indicate strong future performance.
ADMA Biologics has increased its FY25 revenue forecast to exceed $335 million. This indicates that the company expects strong performance in the future, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100